Black Titan (BTTC) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tenaya Therapeutics is the larger company by market cap ($122.0 million vs $6.8 million), about 18.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BTTC | TNYA |
|---|---|---|
| Share price | $0.495 | $0.5442 |
| Market cap | $6.78M | $122.03M |
| 1-day change | -3.51% | +2.02% |
| YTD return | — | -23.57% |
| 1-year return | — | -70.26% |
| 5-year return | — | -97.35% |
| EPS (TTM) | $-0.46 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.05 | $2.35 |
| 52-week low | $0.342 | $0.5211 |
| Distance from 52-week high | -95.07% | -76.84% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +488.02% |
| Average volume | 11.84M | 2.26M |
| Shares outstanding | 13.70M | 224.23M |
| Employees | — | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Tenaya Therapeutics is about 18.0 times larger than Black Titan by market value ($122.03M vs $6.78M).
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
BTTC vs TNYA FAQ
Which is bigger, Black Titan or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $122.03M compared with $6.78M for Black Titan (BTTC).
Are Black Titan and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.